DOCSLIB.ORG

Cannabis Legal & Regulatory Update

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cannabis Legal & Regulatory Update NEWSLETTER Cannabis Legal & Regulatory Update September ­ December 2019 PDF version CONTENT 1. HIGHLIGHTS 2. LATEST LAWS, REGULATORY GUIDANCE AND ENFORCEMENT ACTIONS 2.1. Medical Cannabis 2.2. Well­Being Cannabis 2.3. Recreational Cannabis 3. SELECTED INDUSTRY AND MARKET NEWS The A&O View 2019 was a momentous year for the cannabis industry – this emerging industry is so fast­ moving that it is said to live in dog years. The medical benefits of cannabis and its derivatives have received green light from the international community. During the last quarter of 2019, the first EU­wide marketing authorisation for a cannabis­derived medicinal product was granted by the European Medicines Agency, France continued gearing up for the implementation of its medical cannabis pilot programme, and an increasing number of countries started reimbursing patients for cannabis­based products. National courts (in the UK) have started showing lenience for home­growing cannabis for medical purposes. Meanwhile Big Pharma is – not only – watching and swiftly expanding its cannabis patent portfolio. The CBD landscape, on the other hand, is still characterised by fifty shades of grey. While CBD­based edibles have become a hot commodity on the EU market, the first national regulators and courts (in Finland, Germany…) have now officially banned such products for lack of novel foods authorisation. Will EFSA finally break the deafening silence, and provide some much needed practical guidance, now that a second novel food application – for synthesised CBD – has been filed? If it depends on the European Commission, the EU will unfortunately not wholeheartedly support the – scientifically sensible – WHO recommendations at the next meeting of the Commission on Narcotic Drugs. But make sure to mark 31 March 2020 in your calendars, when the EU Court’s Advocate General is set to provide an important sneak preview into the EU stance towards harmonisation of the CBD well­being market. Indeed, 2020 is gearing up to be an even more critical (dog) year. Cannabis 2.0, bring it on. Wishing you all a flourishing 2020! 1. HIGHLIGHTS EU – European Medicines Agency (EMA) grants first EU­wide marketing authorisation to CBD­based medicine On 19 September 2019, EMA has granted a marketing authorisation to Epidyolex®, a cannabidiol­based orphan medicine indicated for use as adjunctive therapy of seizures associated with Lennox­Gastaut syndrome (LGS) or Dravet syndrome (DS), in conjunction with Clobazam, for patients two years of age and older. The EMA’s Epidyolex detail page is available here EU – EFSA requested to evaluate new novel food application related to synthetic CBD On 26 November 2019, a new application was submitted, after being considered valid by the European Commission, to the European Food Safety Authority (EFSA) requesting a scientific opinion on synthesised trans­cannabidiol as a novel food. EFSA should adopt its opinion within the next nine months. The application is available here EU – European Commission disagrees with WHO ECDD’s recommendations to remove cannabis extracts and tinctures, and preparations containing less than 0,2% from international control regime On 12 December 2019, the European Commission published its proposal for a Council Decision on the position to be taken on behalf of the EU in the 63rd session of the Commission on Narcotic Drugs (CND) during which the vote on ECDD’s recommendations (of January 2019) should take place. The EU only has observer status in the CND and it is necessary for the Council to authorise Member States to express the position of the EU. The Commission agrees with the recommended removal of cannabis and cannabis resin from Schedule IV, but does not support the ECDD’s recommendations (i) to remove “cannabis extracts and tinctures” from Schedule I nor (ii) to clarify that preparations containing less than 0,2% THC are not under international control, and instead requests further assessment by the WHO. The proposal is available here 2. LATEST LAWS, REGULATORY GUIDANCE AND ENFORCEMENT ACTIONS 2.1. MEDICAL CANNABIS AUSTRALIA – Federal Government announces substantial funding for research into medical cannabis benefits On 6 October 2019, The Minister for Health announced that the Australian Government is investing AUS$3 million from the Medical Research Future Fund (MRFF) to examine the benefits of medical cannabis for pain, symptom and side effect management for cancer patients. The Minister for Health press release is available here On 13 November 2019, the Senate inquired the Community Affairs References Committee to examine the degree of patient access of medical cannabis. The committee is to report its findings by 12 February 2020 and should cover in particular the status of the domestic regulated medical cannabis industry, significant financial barriers to accessing medical cannabis treatment, interactions between state and territory authorities and the Commonwealth, and appropriateness of the current regulatory regimes The Senate’s motion is available here and a related article here BARBADOS – Government makes access to medical cannabis possible On 29 November 2019, Barbados adopted a law which regulates the cultivation, licensing and distribution of medicinal cannabis. The law establishes a competent Cannabis Agency, Board and a Medicinal Cannabis Appeals Tribunal and determines the conditions for issuing licences for the handling of medicinal cannabis. In August, the Barbados Drug Service had issued a public tender to supply approved medical cannabinoid products (e.g. dronabinol) starting April 2020 (as such products are currently not available in Barbados). The bill is available here, the call for tender here and a related article here BELGIUM – National Health Agency specifies prescription conditions of CBD products On 16 July 2019, the Belgian Federal Agency for Medicines and Health Products (FAMHP) issued a circular interpreting the Royal Decree of June 2015 on the regulation of products containing one or more tetrahydrocannabinols with regards to raw materials for pharmaceutical compounding. The circular specifies that pharmacists are allowed to dispense some CBD products upon a medical prescription under certain circumstances. Raw material (CBD powder) can be supplied to pharmacies in order to be processed (and then dispensed) with a THC content limited to one microgram per kilogram body weight of a patient per day. The FAMHP circular is available here (FR) BRAZIL – National Health Agency approves medical cannabis pilot but rejects domestic cultivation On 3 December 2019, the Brazilian National Health Agency (ANVISA) rejected a proposal to allow domestic cultivation of medical cannabis but created transitional rules to facilitate the commercialisation of medical cannabis products that have not completed clinical trials. According to ANVISA’s resolution, the new products will only be available in pharmacies and on special medical prescription. The scheme is temporary (similar to medical cannabis pilot programmes in Europe) and will be reviewed in three years. ANVISA’s press release is available here (PT) and a related article here CYPRUS – Government delays bidding process for medical cannabis cultivation On 22 November 2019, the opening of the bidding process for the cultivation of medical cannabis in Cyprus was delayed after government authorities requested a review of the licensing fees. The delay is due to concerns that the licence fees are too low given the revenue growers are expected to generate. A related article is available here CZECH REPUBLIC – Government plans to subsidise the cost of medical cannabis up to 90% On 8 October 2019, the Czech government announced the adoption of a bill that plans to subsidise the cost of medical cannabis from public health insurance funds and that will allow patients to be reimbursed for up to 90% of the cost of their prescription. The Minister of Health’s announcement is available here (CZ) and a related article here DENMARK – Government willing to extend medical cannabis pilot deadlines On 9 December 2019, the Danish Health Minister indicated that the four­year medical cannabis pilot, which is on­going since 1 January 2018, might be extended due to a number of initial difficulties that make it hard to evaluate the results thereof. The evaluation is set to begin in 2020 to help the legislator decide whether to turn this pilot programme into a permanent regime. Related articles are available here (DA) and here ECUADOR – National Assembly allows the medical use of cannabis On 18 September 2019, the National Assembly of Ecuador approved the reform of the Criminal code, the text of which now allows the production, marketing, distribution and use of cannabis for medical purposes in the country. A related article is available here EU – European Medicines Agency (EMA) grants first EU­wide marketing authorisation to CBD­based medicine On 19 September 2019, EMA has granted a marketing authorisation to Epidyolex®, a cannabidiol­based orphan medicine indicated for use as adjunctive therapy of seizures associated with Lennox­Gastaut syndrome (LGS) or Dravet syndrome (DS), in conjunction with Clobazam, for patients two years of age and older. The EMA’s Epidyolex detail page is available here FRANCE – Implementation of national medical cannabis pilot programme underway On 25 October 2019, the French National Assembly adopted the amendment to the 2020 Social Security Financing Bill providing a clear legal basis for the medical cannabis pilot programme. The adopted amendment
Load more

Recommended publications
  • Product Disclosure Statement Initial Public Offering of Ordinary Shares in Rua Bioscience Limited
    Product Disclosure Statement Initial Public Offering of ordinary shares in Rua Bioscience Limited This document gives you important information about this investment to help you 25th September 2020 decide whether you want to invest. There is other useful information about this offer on LEAD MANAGER CO-MANAGER disclose-register.companiesoffice.govt.nz/. Rua Bioscience Limited has prepared this document in accordance with the Financial Markets Conduct Act 2013. You can also seek advice from a financial adviser to help you to make an investment decision. 2 RUA Bioscience Limited • Key information summary Key information summary 1.1 Rua has secured a sales agreement with leading German wholesale importer and distributor Nimbus Health GmbH What is this? (Nimbus), and has developed two commercial-scale facilities: a controlled cultivation facility in Ruatorea and an extraction This is an offer of ordinary shares (Offer Shares) in Rua and manufacturing facility in Gisborne. By prioritising Bioscience Limited (Rua or the Company). Ordinary shares in wholesale exports in the short term, Rua intends to generate Rua give you a stake in the ownership of Rua. You may receive revenue to support its on-going investment into a range of long a return if dividends are paid or Rua increases in value and you term value opportunities, including genetics research, product are able to sell your Shares at a higher price than you paid development, clinical trials and brand development. for them. Rua holds a Medicinal Cannabis Licence from New Zealand’s If Rua runs into financial difficulties and is wound up, you will Medicinal Cannabis Agency, permitting it to operate in be paid only after all creditors have been paid.
    [Show full text]
  • An Economic Perspective on the Legalisation Debate: the Dutch Case
    AN ECONOMIC PERSPECTIVE ON THE LEGALISATION DEBATE: THE DUTCH CASE Martijn Adriaan Boermans* Introduction Understanding the consequences of drug legalisation versus prohibition is important for policy. Most recently this subject has gained much political attention not only globally, but specifically in the Netherlands.1 This study will provide a contribution to the legalisation debate based on a microeconomic analysis of the effects of illegal markets. The research question is how to design a coherent soft drugs policy framework that maximizes social welfare within the Netherlands that precludes most historical, sociological and political debates. In particular, attention is restricted to ‘soft drugs’ better known as cannabis derived products like hashish and marijuana.2 The focus is on the Dutch case, since traditionally the Netherlands has been a forerunner in terms of drug-related policies, as exemplified by coffeeshops. In a country with a population of 16 million about 1 million indicate to use soft drugs on a regular basis. Almost all consumers buy soft drugs in coffeeshops.3 Interestingly, there is no stereotypical Dutch soft drug consumer, since users are representative of the Dutch population, for example in terms of education levels. Prices vary between 150-250 euro per * M.A. Boermans, MPhil, is a PhD Candidate and works for the Innovation and Business Centre (InnBus) at the Hogeschool Utrecht where he also is Lecturer. His other works include economic papers on international trade. He holds a research master degree in Multidisciplinary Economics from the Universiteit Utrecht and obtained his undergraduate degree from the Vrije Universiteit Amsterdam. Corresponding email: [email protected].
    [Show full text]
  • Cannabis in New Zealand Perceptions of Use, Users and Policy
    Cannabis in New Zealand perceptions of use, users and policy Geoff Noller A thesis submitted for the degree of Doctor of Philosophy at the University of Otago, Christchurch Aotearoa, New Zealand November 5, 2008 ABSTRACT Introduction Despite humanity’s lengthy relationship with psychoactive substances, their consumption in contemporary societies is perceived as highly problematic. Cannabis, the most commonly imbibed illicit psychotropic, has come to embody these concerns. Medical and scientific research informs notions of use and user, with these being further constructed in the public realm by law, the media and policy against a backdrop of health deficits and other harms including risk taking, criminality and deviance. With many studies drawing on clinical populations, e.g. high intensity users or those in treatment, a pathologized view of the user predominates. Where general population studies incorporate user data, these typically concentrate on the epidemiology of use: frequency, intensity, duration, and symptoms of abuse and dependence. This, however, tells us little about the meaning of use for users or why use continues despite universal official disapprobation. A lack of studies incorporating user perspectives thus ensures the limited focus of much present research and a policy accent on supply reduction at the expense of harm minimisation and safe use education. Those choosing to continue use are stigmatised as deviant or dependant. This has the effect of further bolstering enforcement, a strategy showing little evidence of efficacy. The present study sought a comparison between this dominant discourse on cannabis use and the perspectives of users, with a range of exploratory hypotheses being identified. Method Eighty cannabis-using respondents participated in open-ended face-to-face interviews, of which seventy-six successfully completed a follow-up questionnaire.
    [Show full text]
  • Mattersofsubstance
    Mattersof Substance. august 2015 Volume 26 Issue No.3 www.drugfoundation.org.nz Taking the pulse of Māori public health Restoring equality and addressing health outcomes for Ma¯ori comes with many challenges. CONTENts FEATURE Taking the STORY pulse of 18 Māori public health COVER: Health inequalities for Mäori remain, but much progress is being made getting the right sort of help COVER ABOUT STORY 06 28 A DRUG WORLD NEWS FEATURE: 02 THE CRUEL C 14 $ $ $ $ ? FEATURES Become 06 14 18 24 a member Taking the pulse of The cruel C The UNGASS A school’s Maori public health With hepatitis C rates 2016 primer core business The New Zealand Drug Foundation has Health inequalities for growing, is there any A comprehensive Focusing on a positive school been at the heart of major alcohol and Mäori remain, but much relief in sight? introduction to the environment means alcohol other drug policy debates for over 20 years. progress is being made UN’s special session on and other drugs aren’t such During that time, we have demonstrated getting the right sort the world drug problem a big deal at Ötaki College a strong commitment to advocating of help policies and practices based on the best evidence available. You can help us. A key strength of the Drug Foundation lies in its diverse membership REGULARS base. As a member of the Drug Foundation, you will receive information about major The Director’s Cut 01 alcohol and other drug policy challenges. You can also get involved in our work to 30 34 36 Events 01 find solutions to those challenges.
    [Show full text]
  • How Fluctuations in the Value of Cocaine Markets Influence the Recourse to Lethal Violence
    International Ph.D. in Criminology – Ph.D. Thesis UNIVERSITÁ CATTOLICA DEL SACRO CUORE MILANO Dottorato di ricerca in Criminologia Ciclo XXIX S.S.D: SPS/12 Shrinking businesses and expanding graveyards: how fluctuations in the value of cocaine markets influence the recourse to lethal violence Tesi di Dottorato di: Alberto Aziani Matricola: 4 2 1 2 2 2 7 Anno Accademico 2015/2016 International Ph.D. in Criminology – Ph.D. Thesis International Ph.D. in Criminology – Ph.D. Thesis Cycle XXIX Shrinking businesses and expanding graveyards: how fluctuations in the value of cocaine markets influence the recourse to lethal violence Ph.D. Thesis Alberto Aziani Academic Year 2015/2016 International Ph.D. in Criminology – Ph.D. Thesis International Ph.D. in Criminology – Ph.D. Thesis 5 International Ph.D. in Criminology – Ph.D. Thesis Abstract Many scholars have investigated the escalation of violence associated with drug trafficking. Despite the plethora of literature, limited attention has been paid to the consequences of fluctuations in the value of markets. This study addresses this lacuna in extant research by proposing an original estimate of the gross value added of cocaine markets in 151 countries between the period 1998-2013, taking into consideration both national and international dimensions of cocaine trafficking through recourse to a flow/network approach. In conjunction with this, the fluctuation of the gross value added of the cocaine market is examined in terms of an etiological factor in the upsurge of interpersonal lethal violence. The analysis demonstrates how expansions and contractions of the gross value added in cocaine markets are significant determinants of the level of violence within the respective countries that constitute the global cocaine network.
    [Show full text]
  • Mattersofsubstance
    Mattersof Substance. february 2013 Volume 24 Issue No.1 www.drugfoundation.org.nz Future drugs All around the world, things are rapidly changing. There are signs the War on Drugs may be running out of steam, new technologies promise new treatment possibilities, and scientific developments may be altering the very nature of drugs themselves. Here in New Zealand, bold new policy initiatives mean the treatment landscape will soon look vastly different. CONTENTS Future ABOUT A DRUG FEATURE: drugs 16 BI INTO BINGE CoveR: slowly the world COVER is starting to realise the STORY FEATURE: 26 War on Drugs has failed. RUSSIAN What does the future hold for 06 DRUG drug policy and recovery? POLICY 22 NZ NEWS BI BINGE? 02 Future drug policy treatments drugs FEATURES Become 20 22 26 30 a member The Drug War Crime and punishment: Putting the ‘bi’ How we see things in retreat? the sorry state of into binge from our front gate The NZ Drug Foundation has been at The UN has been forced to Russian drug policy Recent reports about In 2011, Russell School the heart of major alcohol and other act on the War on Drugs. Russia treats its addicted bisexual binge drinking are became the centre for a drug policy debates for over 20 years. Where to from here? citizens with cruelty. flawed and the reporting battle against Big Alcohol. During that time, we have demonstrated What’s going on behind ridiculous. What’s actually Where is it at now? a strong commitment to advocating the Iron Curtain? going on? policies and practices based on the best evidence available.
    [Show full text]
  • Market Structure for Recreational Cannabis
    BERL REPORTS MINISTRY OF JUSTICE DISCLAIMER JUSTICE 1. This report was prepared by Business and Economic Research Limited (BERL), under commission from the Ministry of OFJustice. 2. The views, opinions, recommendations, and advice expressed in this report belong solely to the authors of the report. The views do not necessarily reflect the views of the Ministry of Justice or the New Zealand Government. 3. The report was one of a number of inputsMINISTRY considered by the Ministry in the development of the draft Cannabis Legalisation and Control Bill. The overarching objective of the regulatory framework, which is set out in theTHE draft Cannabis Legalisation and Control Bill, is to reduce the harms associated with cannabis use experienced byBY individuals, families, whānau, and communities in New Zealand. In developing the model, harm reduction was preferred over other considerations, including economic ones. 4. The report is not part of the Ministry of Justice’s public information campaign for the referendums. RELEASED PROACTIVELY Lot JUSTICE OF MINISTRY THE BY RELEASED Market structure for recreational cannabis Poutū-te-rangi 2020 berl.co.nz PROACTIVELY JUSTICE OF MINISTRY THE BY Authors: Hillmarè Schulze,RELEASED Sam Green, and Hugh Dixon All work is done, and services rendered at the request of, and for the purposes of the client only. Neither BERL nor any of its employees accepts any responsibility on any grounds whatsoever, including negligence, to any other person. While every effort is made by BERL to ensure that the information, opinions and forecasts provided to the client are accurate and reliable, BERL shall not be liable for any adverse consequences of the client’s decisions made in reliance of any report provided by BERL, nor shall BERL be held to have given or implied any warranty as to whether any report provided by BERL will assist in the performance of the client’s functions.
    [Show full text]
  • ©Copyright 2008 Sunil Kumar Aggarwal
    ©Copyright 2008 Sunil Kumar Aggarwal The Medical Geography of Cannabinoid Botanicals in Washington State: Access, Delivery, and Distress Sunil Kumar Aggarwal A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Washington 2008 Program Authorized to Offer Degree: Geography University of Washington Graduate School This is to certify that I have examined this copy of a doctoral dissertation by Sunil Kumar Aggarwal and have found that it is complete and satisfactory in all respects, and that any and all revisions required by the final examining committee have been made. Chair of the Supervisory Committee: ___________________________________________________ Jonathan Mayer Reading Committee: __________________________________________________ Jonathan Mayer _________________________________________________ Richard Morrill ___________________________________________________ Craig ZumBrunnen ___________________________________________________ Gregory Carter ___________________________________________________ Ethan Russo Date:__________________________ In presenting this dissertation in partial fulfillment of the requirements for the doctoral degree at the University of Washington, I agree that the Library shall make its copies freely available for inspection. I further agree that extensive copying of the dissertation is allowable only for scholarly purposes, consistent with “fair use” as prescribed in the U.S. Copyright Law. Requests for copying or reproduction of this dissertation
    [Show full text]
  • EMCDDA Cannabis Reader
    ISSN 1606-1691 A cannabis reader: global issues and local experiences 05 06 15 TD-32-07-001-EN-C About the EMCDDA The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is one of the European Union’s decentralised agencies. Established in 1993 and based in Lisbon, it is the central source of comprehensive information on drugs and drug addiction in Europe. The EMCDDA collects, analyses and disseminates factual, objective, reliable and comparable information on drugs and drug addiction. In doing so, it provides its audiences with an evidence-based picture of the drug phenomenon at European level. The Centre’s publications are a prime source of information for a wide range of audiences including policy-makers and their advisers; professionals and researchers working in the drugs field; and, more broadly, the media and general public. EMCDDA monographs are comprehensive scientific publications containing thematic papers prepared in the context of the Centre’s activities. Topics cover a wide range of issues relating to science, policy, epidemiology and best EMCDDA practice. MONOGRAPHS A cannabis reader: global issues and local experiences Price (excluding VAT) in Luxembourg: EUR 20 per volume MONOGRAPHS EMCDDA VOL. I VOL. 8 8 I VOLUME EMCDDA MONOGRAPHS A cannabis reader: global issues and local experiences Perspectives on cannabis controversies, treatment and regulation in Europe Editors Sharon Rödner Sznitman, Börje Olsson, Robin Room 8 I VOLUME Legal notice This publication of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is protected by copyright. The EMCDDA accepts no responsibility or liability for any consequences arising from the use of the data contained in this document.
    [Show full text]
  • Medicinal Use of Cannabis 3Rd Edition
    M E M O R A N D U M Medicinal use of Cannabis 3rd edition 2015 04/12/2015 Medicines Control & Inspection File no.2013113424/ Axel Heides Gade 1 DK-2300 Copenhagen S Frank Bøgh Madsen [email protected] Email: [email protected] Page 2 04/12/2015 Danish Medicines Agency Contents 1. Introduction ................................................................................................ 3 2. The body's own cannabinoids and receptors .............................................. 3 3. Knowledge about intoxicating and harmful effects and the prevalence of Cannabis......................................................................................................... 4 3.1. The Dutch Ministry of Health's brochure about side effects of medicinal use of Cannabis .......................................................................................... 5 4. Rules about Cannabis as a euphoriant substance ....................................... 6 4.1. List A – Cannabis ............................................................................... 6 4.2. List B – THC in pure form and other cannabinoids ............................ 7 4.3. CBD – in pure form or in hemp products ............................................ 8 5. Positive effects of medicines containing active substances from Cannabis and clinical trials ............................................................................................ 8 5.1. Other scientific evidence about Cannabis and cannabinoids ............ 10 6. Rules about medicines requiring a marketing authorisation (Sativex®)
    [Show full text]
  • MEDICAL CANNABIS in EUROPE: the Markets & Opportunities SECOND EDITION
    MEDICAL CANNABIS IN EUROPE: The Markets & Opportunities SECOND EDITION In-depth look at key European markets and the regulations companies need to understand to tap these revenue opportunities © 2020 Anne Holland Ventures Inc. All Rights Reserved Medical cannabis for German patients We purchase and import EU-GMP medical cannabis into Germany and sell to pharmaceutical wholesalers who supply to pharmacists Subscribe to our newsletter at amp-eu.com/learnmore Medical Cannabis in Europe: The Markets and Opportunity mjbizdaily.com/intl TABLE OF CONTENTS WLECOME LETTER 5 EU MARKET AT A GLANCE 9 GERMANY 14 ITALY 43 THE NETHERLANDS 55 DENMARK 65 CZECH REPUBLIC 74 AUSTRIA AND SWITZERLAND 78 OTHER SMALL MARKETS 80 3 Copyright 2020, Marijuana Business Daily, a division of Anne Holland Ventures Inc. You may NOT copy this report, or make public the data and facts contained herein, in part or in whole. For more copies or editorial permissions, contact [email protected] or call 720.213.5992 ext. 1. RESEARCH DRIVEN LEDs for Compact Plants with High THC/CBD Outputs UV-A Enriched Spectrum for Increased Cannabinoid Production GACP/GMP Facility Suitable Since 2009 we have been committed to creating the best LED grow lights on the market so as to enable growers to increase yields, quality and energy savings. With the largest patent portfolio in the cannabis lighting industry, we are the pioneers of the high quality horticultural LED solutions. 31% 16% 28% more more total more compact plants cannabinoid flowers yield ...than with HPS. 7% 6% 4% more more total more compact plants cannabinoid THC yield ...than with competitor’s LEDs.
    [Show full text]
  • Current Barriers to Patient Access to Medicinal Cannabis in Australia
    The Senate Community Affairs References Committee Current barriers to patient access to medicinal cannabis in Australia March 2020 © Commonwealth of Australia 2020 ISBN 978-1-76093-059-2 (Printed Version) ISBN 978-1-76093-059-2 (HTML Version) This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Australia License. The details of this licence are available on the Creative Commons website: http://creativecommons.org/licenses/by-nc-nd/3.0/au/. Printed by the Senate Printing Unit, Parliament House, Canberra Committee Members Chair Senator Rachel Siewert AG, WA Deputy Chair Senator Wendy Askew LP, TAS Members Senator Catryna Bilyk ALP, TAS (from 5 February 2020) Senator Raff Ciccone ALP, VIC (from 5 December 2019 to 5 February 2020) Senator Hollie Hughes LP, NSW Senator Malarndirri McCarthy ALP, NT Senator Anne Urquhart ALP, TAS Participating Members Senator Catryna Bilyk ALP, TAS (until 5 February 2020) Senator Richard Di Natale AG, VIC Former Members Senator Deborah O'Neill ALP, NSW (until 5 December 2019) Secretariat Jeanette Radcliffe, Committee Secretary Apolline Kohen, Principal Research Officer Kathleen McGarry, Acting Senior Research Officer Carol Stewart, Administrative Officer PO Box 6100 Parliament House Canberra ACT 2600 Phone: 02 6277 3515 Fax: 02 6277 5829 E-mail: [email protected] Internet: www.aph.gov.au/senate_ca iii Table of Contents Committee Members ........................................................................................................................ iii
    [Show full text]